Skip to main content

Grafa News and Videos — Page 1513

Latest

Grafa

IDEAYA announces positive Phase 2/3 data in metastatic uveal melanoma

IDEAYA Biosciences (NASDAQ:IDYA) and Servier reported breakthrough topline results today from the Phase 2/3 OptimUM-02 trial, demonstrating that the combination of darovasertib and crizotinib significantly improved outcomes for patients with first-line HLA-A*02:01-negative metastatic uveal melanoma (MUM).

Read more: IDEAYA announces positive Phase 2/3 data in metastatic uveal melanoma

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift